J. Popp

Discipline

Psychologie (31) Histoire, Philosophie et Sociologie des sciences (2) Anthropologie biologique (1)

Type de document

Articles (63) Recensions (5) Autres (1)

Co-auteur

Date

Source

Mot-clé

Alzheimer's disease (50) Dementia (37) Amyloid (34) Human beings (34) Biochemical markers (34) Cerebrospinal fluid (33) maladie (32) maladie (32) biomarqueur (31) pathologie (29) Pathology (29) Older people (29) âge (26) Cognition (26) Age (26) Age (26) risque (23) association (23) analyse (23) Social groups (23) Risk (23) Analysis (23) Mild cognitive impairment (22) Proteins (21) Apolipoprotein E (20) Disabilities (20) protéine (19) Performance (18) Patients (18) Patients (18)

Documents écrit par J. Popp (64) | parle de J. Popp (0)

Paired plasma lipidomics and proteomics analysis in the conversion from mild cognitive impairment to Alzheimer's disease.
T. Naccache et al.
Plasma neurofilament light, glial fibrillary acid protein, and phosphorylated tau 181 as biomarkers for neuropsychiatric symptoms and related clinical disease progression.
M. Rabl et al. (22 mars 2024)
Association between Serum Phytosterols and Lipid Levels in a Population-Based Study.
L. Stanasila et al. (8 mars 2024)
Cholesterol-metabolism, plant sterols, and long-term cognitive decline in older people - Effects of sex and APOEe4.
M. Spinedi et al. (16 févr. 2024)
Multivariate GWAS of Alzheimer's disease CSF biomarker profiles implies GRIN2D in synaptic functioning.
A. Neumann et al. (4 oct. 2023)
Multiancestry analysis of the HLA locus in Alzheimer's and Parkinson's diseases uncovers a shared adaptive immune response mediated by HLA-DRB1*04 subtypes.
Y. Le Guen et al. (5 sept. 2023)
Multiomics profiling of human plasma and cerebrospinal fluid reveals ATN-derived networks and highlights causal links in Alzheimer's disease.
L. Shi et al.
Plant sterols and cholesterol metabolism are associated with five-year cognitive decline in the elderly population.
C. Clark et al. (16 juin 2023)
Whole-exome rare-variant analysis of Alzheimer's disease and related biomarker traits.
F. Küçükali et al.
Genetic Associations Between Modifiable Risk Factors and Alzheimer Disease.
J. Luo et al. (1 mai 2023)
Obstructive sleep apnoea and 5-year cognitive decline in the elderly.
N.A. Marchi et al.
Author Correction: Common variants in Alzheimer's disease and risk stratification by polygenic risk scores.
I. de Rojas et al. (9 févr. 2023)
Persisting neuropsychiatric symptoms, Alzheimer's disease, and cerebrospinal fluid cortisol and dehydroepiandrosterone sulfate.
S. Ouanes et al. (19 déc. 2022)
Biomarqueurs des pathologies neurodégénératives dans le diagnostic des troubles cognitifs - Revue et recommandations de Swiss Memory Clinics [Biomarkers for the diagnosis of cognitive impairment - Recommendations from the Swiss Memory Clinics]
J. Popp et al. (14 déc. 2022)
Genome-wide meta-analysis for Alzheimer's disease cerebrospinal fluid biomarkers.
I.E. Jansen et al.
Characteristics of subjective cognitive decline associated with amyloid positivity.
O. Janssen et al.
Recommandations pour la prévention, le diagnostic et la thérapie des addictions à l’âge avancé [Recommendations for the prevention, diagnosis, and therapy of addiction in the elderly]
J. Popp et al. (28 sept. 2022)
Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected non-Alzheimer's disease pathophysiology.
A. Delvenne et al. (14 juin 2022)
Systemic and central nervous system neuroinflammatory signatures of neuropsychiatric symptoms and related cognitive decline in older people.
C. Clark et al. (28 mai 2022)
Correction: Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease.
P.J. Visser et al. (13 mai 2022)
Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer's disease CSF profile of neuronal injury and inflammation.
A. Neumann et al.
New insights into the genetic etiology of Alzheimer's disease and related dementias.
C. Bellenguez et al.
Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease.
P.J. Visser et al. (28 mars 2022)
Cerebrospinal Fluid Proteome Alterations Associated with Neuropsychiatric Symptoms in Cognitive Decline and Alzheimer's Disease.
M. Mroczek et al. (18 mars 2022)
Predicting AT(N) pathologies in Alzheimer's disease from blood-based proteomic data using neural networks.
Y. Zhang et al. (2022)

next